Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30870371 | 1.00 | KMT2A (0.60) | KMT2ACHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL11040087 | 0.93 | MAPT (0.53) | KMT2ACHRM2CHRM1CHRM5CHRM3 | |
| Benzoic Acid SCHEMBL28108053 | 0.92 | KMT2A (0.51) | KMT2ACHRM2CHRM1CHRM5CHRM3 | |
| Phenylacetic Acid SCHEMBL28835698 | 0.89 | AKR1B1 (0.52) | KMT2ACHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL18381730 | 0.85 | KMT2A (0.60) | KMT2ALMNAKDM4EMEN1POLB | |
| SCHEMBL18381729 | 0.85 | KMT2A (0.60) | KMT2ALMNAKDM4EMEN1POLB | |
| SCHEMBL29425354 | 0.85 | KMT2A (0.60) | KMT2ALMNAKDM4EMEN1POLB | |
| SCHEMBL174166 | 0.85 | KMT2A (0.60) | KMT2ALMNAKDM4EMEN1POLB | |
| SCHEMBL28601780 | 0.83 | KMT2A (0.50) | KMT2ACHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL10773175 | 0.83 | KMT2A (0.58) | KMT2ALMNAMEN1TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105985241-A | Inhibition effect of [alpha]-substituted phenyl acetate compounds on [alpha]-glycosidase and application of the compounds | 邵阳学院 | 2016-10-05 | — | — | CN | claimed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| CN-1167407-C | Skin deodorizing and sanitizing compositions | 宝洁公司 | 2004-09-22 | — | — | CN | claimed |
| CN-113354635-B | Pyrrolidine integrin regulator and application thereof | 清药同创(北京)药物研发中心有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-110551027-B | Synthetic method of 3-hydroxy-2-phenylpropionic acid | 南京理工大学 | 2022-03-22 | — | — | CN | disclosed |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2021-11-25 | — | — | US | disclosed |
| CN-113354635-A | Pyrrolidine integrin regulator and application thereof | 清药同创(北京)药物研发中心有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3828172-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10654844-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-5686489-A | TOPICALLY APPLIED TO INDUCE GLYCOSAMINOGLYCAN, PROTEOGLYCAN, COLLAGEN AND ELASTIN BIOSYNTHESIS; WRINKLE RESISTANCE | TRISTRATA TECHNOLOGY, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1996040047-A1 | ALPHA HYDROXYACID ESTERS FOR SKIN AGING | YU RUEY J (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5492930-A | ADMINISTERING 2-PHENYL-1,3-PROPANEDIOL MONOCARBAMATE | SCHERING CORPORATION (US) | 1996-02-20 | — | — | US | disclosed |
| WO-1994006737-A1 | PROCESS FOR PREPARING FELBAMATE, 2-PHENYL-1,3-PROPANEDIOL AND INTERMEDIATES | SCHERING CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0588652-A1 | Process for the preparation of 2-aryl-1,3-propanediols | GANES CHEMICALS INC. (US) | 1994-03-23 | — | — | EP | disclosed |
| CN-1078745-A | The liquid hard surface detergent compositions that contains tensio-active agent and alkanolamine | PROCTER & GAMBLE (US) | 1993-11-24 | — | — | CN | disclosed |
| US-5250744-A | Process for the preparation of 2-aryl-1,3-propanediols | GANES CHEMICALS INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5239121-A | Process for the preparation of 2-aryl-1,3-propanediols | GANES CHEMICALS INC. (US) | 1993-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654844-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | KMT2A 3013/4885CHRM2 470/4885CHRM1 863/4885 |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | KMT2A 3013/4885CHRM2 470/4885CHRM1 863/4885 |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | KMT2A 3013/4885CHRM2 470/4885CHRM1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.